TD Cowen initiated coverage of Disc Medicine (IRON) with a Buy rating and no price target The shares are pricing in an opportunity for bitopertin that assumes a modest penetration of the “low ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback
